BHVN
Price
$13.14
Change
+$1.22 (+10.23%)
Updated
Jan 16 closing price
Capitalization
1.74B
60 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$33.24
Change
+$0.15 (+0.45%)
Updated
Jan 16 closing price
Capitalization
2.58B
39 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BHVN vs SYRE

Header iconBHVN vs SYRE Comparison
Open Charts BHVN vs SYREBanner chart's image
Biohaven
Price$13.14
Change+$1.22 (+10.23%)
Volume$4.13M
Capitalization1.74B
Spyre Therapeutics
Price$33.24
Change+$0.15 (+0.45%)
Volume$439.33K
Capitalization2.58B
BHVN vs SYRE Comparison Chart in %
BHVN
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BHVN vs. SYRE commentary
Jan 18, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHVN is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 18, 2026
Stock price -- (BHVN: $13.14 vs. SYRE: $33.24)
Brand notoriety: BHVN and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BHVN: 107% vs. SYRE: 59%
Market capitalization -- BHVN: $1.74B vs. SYRE: $2.58B
BHVN [@Biotechnology] is valued at $1.74B. SYRE’s [@Biotechnology] market capitalization is $2.58B. The market cap for tickers in the [@Biotechnology] industry ranges from $111.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHVN’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • BHVN’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, BHVN is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHVN’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 3 bullish TA indicator(s).

  • BHVN’s TA Score: 6 bullish, 3 bearish.
  • SYRE’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BHVN is a better buy in the short-term than SYRE.

Price Growth

BHVN (@Biotechnology) experienced а +18.27% price change this week, while SYRE (@Biotechnology) price change was +8.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was +4.14%, and the average quarterly price growth was +42.40%.

Reported Earning Dates

BHVN is expected to report earnings on Mar 19, 2026.

SYRE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($2.58B) has a higher market cap than BHVN($1.74B). BHVN YTD gains are higher at: 16.386 vs. SYRE (1.465). SYRE has higher annual earnings (EBITDA): -223.64M vs. BHVN (-782.76M). SYRE has more cash in the bank: 486M vs. BHVN (260M). SYRE has less debt than BHVN: SYRE (0) vs BHVN (314M). BHVN (0) and SYRE (0) have equivalent revenues.
BHVNSYREBHVN / SYRE
Capitalization1.74B2.58B68%
EBITDA-782.76M-223.64M350%
Gain YTD16.3861.4651,118%
P/E RatioN/A1.72-
Revenue00-
Total Cash260M486M53%
Total Debt314M0-
FUNDAMENTALS RATINGS
BHVN vs SYRE: Fundamental Ratings
BHVN
SYRE
OUTLOOK RATING
1..100
8765
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6138
P/E GROWTH RATING
1..100
10081
SEASONALITY SCORE
1..100
4750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BHVN's Valuation (39) in the Pharmaceuticals Major industry is in the same range as SYRE (71). This means that BHVN’s stock grew similarly to SYRE’s over the last 12 months.

BHVN's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that BHVN’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as BHVN (100). This means that SYRE’s stock grew similarly to BHVN’s over the last 12 months.

SYRE's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as BHVN (61). This means that SYRE’s stock grew similarly to BHVN’s over the last 12 months.

SYRE's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as BHVN (100). This means that SYRE’s stock grew similarly to BHVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHVNSYRE
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 7 days ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
76%
Bearish Trend 14 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
BHVN
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RRREX22.110.25
+1.14%
DWS RREEF Real Estate Securities S
CHCCX13.990.10
+0.72%
AB Discovery Growth C
RIIEX46.280.06
+0.13%
American Funds Intl Gr and Inc R2E
PECAX15.910.01
+0.06%
JPMorgan SMID Cap Equity A
GLNAX24.67-0.03
-0.12%
MFS Global New Discovery A

BHVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHVN has been loosely correlated with SYRE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BHVN jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHVN
1D Price
Change %
BHVN100%
+10.23%
SYRE - BHVN
47%
Loosely correlated
+0.45%
BCYC - BHVN
45%
Loosely correlated
+0.62%
VCYT - BHVN
43%
Loosely correlated
+1.39%
TERN - BHVN
43%
Loosely correlated
-1.03%
CGON - BHVN
43%
Loosely correlated
+3.13%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+0.45%
ORKA - SYRE
58%
Loosely correlated
+2.77%
XNCR - SYRE
58%
Loosely correlated
-3.18%
BEAM - SYRE
57%
Loosely correlated
-2.59%
RGNX - SYRE
55%
Loosely correlated
-1.02%
APGE - SYRE
55%
Loosely correlated
+0.02%
More